Pair Name | Toosendanin, Regorafenib | ||
Phytochemical Name | Toosendanin (PubChem CID: 9851101 ) | ||
Anticancer drug Name | Regorafenib (PubChem CID: 11167602 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Toosendanin, Regorafenib | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Inhibition-->Cell metastasis | |||
Gene Regulation | Down-regulation | Expression | DVL2 | hsa1856 |
Up-regulation | Phosphorylation | GSK3B | hsa2932 | |
Down-regulation | Expression | MMP2 | hsa4313 | |
Down-regulation | Expression | MMP9 | hsa4318 | |
Down-regulation | Expression | MYC | hsa4609 | |
Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
Up-regulation | Expression | WWOX | hsa51741 | |
In Vitro Model | MHCC97-L | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_4973 |
Result | TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC |
No. | Title | Href |
---|---|---|
1 | Synergistic effect of toosendanin and regorafenib against cell proliferation and migration by regulating WWOX signaling pathway in hepatocellular carcinoma. Phytother Res. 2021 Aug;35(8):4567-4578. doi: 10.1002/ptr.7174. | Click |